In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Bionics to Stimulate Growth for Boston Scientific

Executive Summary

Investors approved of Boston Scientific's decision to purchase Advanced Bionics, which offers a wealth of new possibilities in areas in which BSC is already a leader--cardiology, urology, neurology, and gastroenteroloy. More than that, Advanced Bionics presents completely new and untapped businesses in neurostimulation.
Advertisement

Related Content

Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD
Neuromodulation: Devices's Stimulating Growth Market
Stimulating Growth: St. Jude buys ANS
Neuronetics Inc.
Frazier's Commitment to Early-Stage Device Dealmaking Pays Off
Cameron Health and the Revolution From Below
Cyberonics and Depression's Happy Face
Cyberonics: Nearly Half-way to the Summit, Fueled by Positive Data and Boston Scientific's investment
ANS Goes Along For The Ride
Cyberonics On Its Own

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel